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Abstract
Objective: TNF inhibitors (TNFi) have revolutionised the treatment of rheumatoid arthritis (RA). Natural killer (NK) cells and
Natural Killer Cell Receptor
+ T (NKT) cells comprise important effector lymphocytes whose activity is tightly regulated
through surface NK receptors (NKRs). Dysregulation of NKRs in patients with autoimmune diseases has been shown,
however little is known regarding NKRs expression in patients with TNFi-induced remission and in those who maintain
remission vs disease flare following TNFi withdrawal.
Methods: Patients with RA were recruited for this study, (i) RA patients in clinical remission following a minimum of one year
of TNFi therapy (n=215); (2) Active RA patients, not currently or ever receiving TNFi (n=18); and healthy control volunteers
(n=15). Patients in remission were divided into two groups: those who were maintained on TNFi and those who withdrew
from TNFi and maintained on DMARDS. All patients underwent full clinical assessment. Peripheral blood mononuclear cells
were isolated and NKR (CD94, NKG2A, CD161, CD69, CD57, CD158a, CD158b) expression on T-(CD3
+CD56
2), NK-
(CD3
2CD56
+) and NKT-(CD3
+CD56
+) cells was determined by flow cytometry.
Results: Following TNFi withdrawal, percentages and numbers of circulating T cells, NK cells or NKT cell populations were
unchanged in patients in remission versus active RA or HCs. Expression of the NKRs CD161, CD57, CD94 and NKG2A was
significantly increased on CD3
+CD56-T cells from patients in remission compared to active RA (p,0.05). CD3
+CD56-T cell
expression of CD94 and NKG2A was significantly increased in patients who remained in remission compared with patients
whose disease flared (p,0.05), with no differences observed for CD161 and CD57. CD3
+CD56
2 cell expression of NKG2A
was inversely related to DAS28 (r=20.612, p,0.005).
Conclusion: High CD94/NKG2A expression by T cells was demonstrated in remission patients following TNFi therapy
compared to active RA, while low CD94/NKG2A were associated with disease flare following withdrawal of therapy.
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Introduction
Rheumatoid arthritis (RA) is the most common form of
inflammatory arthritis affecting 1% of the population. Left
untreated RA leads to joint deformity and disability [1]. RA is
characterised by symmetrical erosive polyarthritis, with extra-
articular manifestations in some patients. Activated T cells and
innate cells such as macrophages contribute to the development of
synovial inflammation by secreting TNFa, a potent pro-inflam-
matory cytokine [2]. TNFa inhibits both bone formation and
proteoglycan synthesis while inducing bone and proteoglycan
resorption. It also stimulates metalloproteinase and collagenase
production, triggers inflammatory cytokine cascades and increases
adhesion molecule expression by infiltrating immune cells. TNF
inhibitors (TNFi) improve disease activity indices (clinical and
laboratory) and inhibit radiographic progression [326]. The use of
TNFi has revolutionised the treatment of RA patients, particularly
in patients with moderate to severe RA [327].
However, TNFi are expensive and have potential for serious
side-effects. Prior to routine use of biologic therapies, the average
annual medical cost for a patient with RA was $8500 [8]. Studies
have demonstrated mean annual costs of TNFi between $12,146
and $15,617 depending on the agent prescribed. When other
expenses are taken into account, e.g. administration in an OPD
setting and concomitant disease modifying anti-rheumatic drug
(DMARD) use, the cost may rise to $18,046 [9,10]. An important
goal for rheumatologists treating RA patients is to identify markers
that can (1) predict response to TNFi, (2) predict remission rates
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27182and (3) predict those patients who can maintain remission
following withdrawal of TNFi [11,12].
Natural killer cells (NK), T cells and natural killer T (NKT) cells
participate in aetiology and regulation of RA pathogenesis
[13216]. NK cells are key players in innate immunity, their
primary function killing of virally infected or transformed cells.
They can also regulate the adaptive immune response through
their ability to produce cytokines. The activity of NK cells is tightly
controlled through a variety of stimulatory, co-stimulatory and
inhibitory receptors (NKRs) [17]. Dysregulated expression of
NKRs and impairment of NK function have been demonstrated in
RA. For example, increased expression of the CD94 receptor with
concomitant reduction in the expression of inhibitory Killer Ig-
Like Receptors (KIR) has been demonstrated in patients with RA
[13]. In addition, Richter et al. have recently demonstrated that
the NK receptor CD161 contributes to impairment of NK cell
cytotoxicity and responsiveness to specific ligands in patients with
RA [14].
T cells that co-express NKRs comprise approximately 5215%
of the peripheral T cell pool and have the ability to mediate
functions of both T and NK cells. These cells may also express
activatory or inhibitory NKRs e.g. CD94/NKG2A (inhibitory) or
NKG2D (activatory) and are known as NK receptor
+ T cells
(NKT cells) [18]. Levels of NKR+ T cells are increased in the
peripheral blood and synovial tissue of patients with active RA
[15,19]. High levels of IL-15 and TNFa in RA patients contribute
to the expansion of the NKG2D
+ T cell population, cells that may
have greater autoreactive potential due to their high expression of
activatory receptors [15]. A significant proportion of T cells
(CD4
+CD28
2) expressing NKG2D display autoreactive responses
against RA synovial fibroblasts [15,20]. Furthermore increased
expression of activatory KIR receptor KIR2DS2 on CD4
+CD28
2
cells have been shown to correlate with RA disease activity [21].
The aim of this study was to examine NK receptor expression
on lymphoid phenotypes in patients in TNFi-induced remission
compared to active disease, and to investigate their expression in
patients with continued remission compared to disease flare
following TNFi withdrawal.
Methods
Patient Cohorts
All research was carried out in accordance with the Declaration
of Helsinki and approval for this study was granted by the St.
Vincent’s University Hospital medical research and ethics
committee. Rheumatoid arthritis (RA) patients diagnosed accord-
ing to the criteria of the American College of Rheumatology [22]
were recruited from the rheumatology outpatient clinics at St.
Vincent’s University Hospital (SVUH). This study was approved
by the SVUH Medical Research and Ethics Committee; all
patients provided fully-informed written consent. Two cohorts of
patients with RA were recruited from the Rheumatology clinics,
St. Vincent’s University Hospital; (1) RA patients in clinical
remission 28 joint disease activity score (DAS28) ,2.6 for 6
months] (n=15) following a minimum of one year of TNFi
therapy; and (2) Active RA patients, not currently or ever receiving
TNFi (n=18). All patients fulfilled the American College of
Rheumatology criteria for RA. Healthy control volunteers were
also recruited (n=15).
The RA remission group were subsequently divided into two
groups, those that continued on TNFi therapy or those that were
withdrawn from biologic therapy and maintained on substituted
optimal DMARD therapy.
Clinical and laboratory assessments were performed in
remission patients at baseline, 1, 3 and 6 months. After 6 months,
patients who continued TNFi were given the further option of
withdrawing and substituting optimal DMARD therapy. Full
clinical and laboratory assessments were also performed in the
active RA group. Clinical assessment included physical examina-
tion and joint counts. Erythrocyte Sedimentation Rate (ESR) and
C-reactive protein (CRP) were measured and the DAS28
calculated at each visit. Functional assessment using the health
assessment questionnaire-disability index (HAQ-DI) was per-
formed. Short-form236 (SF-36) data was collected at baseline
and 6 months (or study termination, if earlier). RA patients
experiencing a disease flare were treated according to best clinical
practise with corticosteroids #20 mg/day reducing over 2 weeks
plus recommencement of TNFi if appropriate.
Peripheral blood mononuclear cell separation
Fifteen ml of heparinised blood was collected at baseline from
each participant and at each clinic visit thereafter from patients in
the remission cohort. PBMCs were isolated by density gradient
centrifugation (Lymphoprep; Nycomed, West Midlands, UK).
Cells were washed in Roswell Park Memorial Institute (RPMI)-
1640 (Gibco-BRL, Paisley, UK) supplemented with penicillin
(100units/mL; Biosciences), streptomycin (100units/mL; Biosci-
ences) and fungizone (0.25mg/mL; Biosciences) (sRPMI) and
cryopreserved (20% Dimethyl Sulphoxide in fetal bovine serum,)
for subsequent analysis. It has previously been demonstrated that
cryopreservation does not alter immunological characteristics of
NK cells [23].
Flow cytometric analysis of cell surface antigens
Fluorochrome-labelled (fluorescein isothiocyanate (FITC)/phy-
coerythrin [PE]/peridinin-chlorophyll-protein complex (PerCP))
monoclonal Abs (MAbs) specific for CD3, CD4, CD8, CD56,
CD161, CD94, CD158a, CD158b, HLA-DR and CD57 were
obtained from BD Biosciences (Oxford, UK). Anti-NKG2A-PE
was obtained from Immunotech (Beckman Coulter, Fullerton,
CA). PBMCs were defrosted in warmed sRPMI and resuspended
at a concentration of 1 million cells per millilitre of sRPMI.
PBMCs (2.5610
5 cells) were stained for cell surface antigen
expression at 4uC in the dark for 30 min. Cells were then washed
twice in phosphate buffered saline (PBS) and fixed in 1%
paraformaldehyde (PFA) until analysis. Cells were acquired using
a BD FACSCalibur instrument (BD Biosciences) and analysed
using CellQuest software (BD Biosciences).
Statistical analysis
Statistical analysis was performed using SPSS version 12.1.0 for
Windows. Non-parametric Mann Whitney U-test was used to
compare differences between study cohorts and non-parametric
Wilcoxon Signed Rank for related samples. Significance was
defined as a p value ,0.05. Correlation coefficients were
determined using Spearman’s test.
Results
Patient demographics
Baseline characteristics of remission and active RA patients
cohorts are shown in (Table 1). Fifteen patients in remission were
recruited, ten (66%) patients were female with a mean (SEM) age
of 50.27 (4.08) years, disease duration of 9.63 (1.96) years, ESR
8.73 (1.38) mm/hr, CRP 6.00 (1.02) mg/L and 12 (80%) patients
were rheumatoid factor positive (RF+). Patients were divided into
those who were maintained on therapy compared with those
CD94 and NKG2A and Remission
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demonstrated between the two groups. Nine of fifteen (60%)
patients: (female, n (%), 6 (66.67); age, mean years (SEM), 50.0
(5.6); RF+, n (%), 9 (81.81)) continued on TNFi therapy (Table 2).
After 6 months, five of these patients consented to withdraw TNFi
therapy. Six patients withdrew TNFi therapy initially and five at 6
months, giving a total of 11 TNFi withdrawal patients (female, n
(%), 7 (63.64%); age, mean years (SEM), 52.6 (4.1); RF+, n (%), 6
(66.67)). One patient had a flare in disease activity two weeks after
TNFi withdrawal, did not respond to corticosteroids and
recommenced their TNFi. No significant difference was seen in
clinical, functional assessment (HAQ, SF-36) and laboratory
markers of inflammation (ESR CRP) at six months in both groups
(Table 2).
Active RA patients (n=18; female, n (%) (12 (63.16)) and fifteen
healthy controls (12 (80%)) were recruited (Table 1). The mean
(SEM) age of the active RA group was 57.00 (3.04) years and
healthy controls 41.67 (2.63) years. Clinical characteristics for the
RA patients included mean ESR of 35.2464.87 mm/hr, CRP of
26.2966.32 mg/L, and disease duration of 3.7260.55 years.
Thirteen (86.67%) were RF+.
T cell populations in remission patients, active RA and
controls
No difference was demonstrated in percentages of totals of
classic T cells or NK cells, (expressed as a percentage of the
lymphogates) between patients in remission, patients with active
RA or controls (Figure 1A). Furthermore, no significant difference
was observed for percentages of NKT(CD3+CD562), NK (CD3-
D56+) or T (CD3+CD56+) cell populations (Figure 1B).
Expression of NK surface receptors CD161, CD57 and
HLA-DR by T cells
Expression of CD161 by T cells was significantly increased in
remission patients (4.1160.78%) compared to active RA
(1.3960.27%) (p=0.005) (Figure 2A,B). CD161 expression in
remission was not significantly different to levels expressed by the
CD3+CD562 cells of the control group (2.2860.45%) (p=0.155).
Furthermore, an increased proportion of CD3
+CD56
2 T cells
were CD57
bright in both the remission and control groups
(5.1760.88% and 6.7162.01%) compared to the active RA
group (2.5760.50%) (p=0.019 and 0.033 respectively) (Figure 2).
Expression of HLA-DR on CD3+CD562 cells was similar in
remission (6.4861.24%), active RA (4.4960.53% (p=0.406)) and
controls (7.4061.77% (p=0.873)). Furthermore, no difference was
observed for CD161, CD57 and HLA-DR expression on
CD56+CD32 or CD56+CD3+ cells between the 3 groups (data
not shown). No significant difference was observed for CD57
expression in remission compared to controls (p=0.986). No
significant difference was seen in the expression of HLA-DR on
CD3+CD562 cells in remission (6.4861.24%) compared to
active RA (4.4960.53% (p=0.406)) or controls (7.4061.77%
(p=0.873)). Furthermore, no difference was observed for CD161,
Table 1. Baseline characteristics of patients in remission following TNF inhibitor therapy and in patients with active rheumatoid
arthritis.
Remission Cohort Active RA Cohort p value
Female, n (%) 10(66) 12(66.67) p=ns
Age, mean(sem) 50.27(4.08) 57.00(3.04) p=ns
Disease duration, mean (sem) 9.63(1.96) 3.72(0.55) p=(0.004)
Rheumatoid factor +, n (%) 12(80) 16(88.89) p=ns
ESR(mm/hr), mean(sem) 8.73(1.38) 35.24(4.87) p=0.00003
CRP(mg/L), mean (sem) 6.00(1.02) 26.29(6.32) p=0.004
*p,0.05 remission cohort significantly different from active RA cohort.
doi:10.1371/journal.pone.0027182.t001
Table 2. Clinical, laboratory and functional assessments in patients cohorts maintaining and withdrawing TNF inhibitor therapy.
Withdrawal of anti-TNF Therapy Maintain anti-TNF therapy
Baseline 3 months 6 months Baseline 3months 6months
TJC(0–28) mean6sem 0.3660.15 0.8260.54 0.9160.56 0.5660.00 0.1160.22 0.4460.24
SJC (0-28) mean6sem 0.3660.28 0.6460.59 0.9160.58 0.0060.38 0.2260.11 0.3360.24
ESR (mm Hg) mean6sem 9.2061.83 9.2061.91 9.2062.11 8.5661.84 8.5762.20 7.8961.93
CRP (mg/dl) mean6sem 7.3661.68 8.1863.02 8.5563.28 4.3360.33 4.5060.47 4.2260.22
VAS(0-100 mm) mean6sem 13.8263.56 14.2765.75 18.9165.25 15.2265.30 28.2567.70* 21.8665.22
DAS28 mean6sem 1.8860.18 1.8860.43 2.0260.42 1.8260.27 1.8060.25 1.9460.20
HAQ (0–3) mean6sem 0.21660.000 0.33360.047 0.29660.125 0.27860.062 0.42260.077 0.39360.070
SF-36 PCS mean6sem 45.4362.73 46.1462.93 45.5063.34 41.2263.06
SF-36 MCS mean6sem 56.4362.3 53.0563.13 53.5063.16 50.4763.46
*p,0.05 vs baseline.
doi:10.1371/journal.pone.0027182.t002
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CD56+CD3+ cells between the 3 cohorts.
CD94 and NKG2A expression on CD3+CD562 cells
A significant increase in CD94 expression was found in
remission (2.1660.31%) compared to active RA (1.3360.29%)
(p=0.017). This was accompanied by a significant increase in the
expression of the inhibitory receptor, NKG2A, in remission
(2.6760.37%) compared to active RA (1.7660.48%) (p=0.031)
(Figure 3A,B). Furthermore, NKG2A and CD94 expression was
similar in remission compared to controls (2.6160.39%)
(p=0.957) (Figure 3). No significant differences were observed
for expression of the inhibitory KIR, CD158a and CD158b, in
remission (0.0960.02% and 0.9360.32% respectively), active RA
(0.0560.01% and 0.6660.14%) or controls (0.1460.05% and
1.1260.64%). Finally, we observed no difference in CD94 and
NKG2A expression on CD56+CD32 or CD56+CD3+ popula-
tions between the 3 cohorts (data not shown).
T cell populations in patients maintaining or withdrawing
TNFi
Total numbers of CD3+ cells significantly decreased from
58.0564.98% to 44.1665.75% in patients maintained on therapy
(p=0.06) (Figure 4A), in contrast to total CD56+ NK cells where
no difference was observed (Figure 4A). CD3+CD562 T cells also
decreased from 51.2064.11% to 37.5365.24% (p=0.04)) in
patients maintaining therapy (Figure 4B). No significant difference
was observed between the frequency of the CD3+ population of
lymphocytes at baseline (54.3364.36%) compared to the three
month time-point (56.0663.57%) in the patient cohort withdraw-
ing therapy (p=0.78).
CD94 and NKG2A expression in patients maintaining or
withdrawing TNFi
A significant increase in CD94 expression on CD3+CD562 T
cells at three months (5.5961.34%) compared to baseline
(2.3360.48%) was demonstrated in patients maintaining TNFi
(p=0.03). This was accompanied by a significant increase in
CD3+CD562 expression of inhibitory receptor NKG2A
(2.7460.49% at baseline compared to 5.5961.34% at 3 months
(p=0.02)) (Figure 5A). No difference was observed in expression of
the inhibitory KIR, CD158a or CD158b, in either cohort between
baseline and three months (data not shown). Figure 5C shows
representative flow cytometry dot plots from 2 patients who withdrew
TNFi. Patient 1 maintained remission throughout the study period.
No change was observed in CD94 or NKG2A expression between
Figure 1. T cell, NK and NKT cell populations in active RA, Remission RA and healthy controls. Graph illustrating T cell, NK and NKT cell
populations in healthy controls (N=15) (m), patients with active RA (n=18) (#) and patients in remission following TNF inhibitor (n=15)(&).
*p,0.05 significantly different.
doi:10.1371/journal.pone.0027182.g001
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flare in disease activity (DAS28.2.6) at six months. A reduction in
the expression of CD94 and NKG2A on CD3+CD562 cells was
demonstrated at the three month follow-up prior to clinical evidence
of a flare in disease activity, suggesting reduced expression of CD94/
NKG2A may be associated with RA flare.
CD161 expression was significantly higher in the group
maintaining therapy at 3 months (6.0861.39%) compared to
baseline (3.9761.24%) (p=0.04). CD57 expression was also higher
at 3 months (8.3963.98%) compared to baseline (4.8361.40%) but
this did not reach statistical significance. (Figure 5B). We did not
observe changes in the expression of CD161 or CD57 by the
CD3+CD562 population of lymphocytes at three months in the
patient cohort withdrawing TNFi (Figure 5B).
Loss of CD94/ NKG2A expression is associated with flare
in disease activity after withdrawal of TNFi
Figure 6A demonstrates DAS28 and NKG2A expression by T
cells in patients who withdrew from or remained on TNFi. Open
boxes represents patients who flared and grey boxes represents
patients who stayed in remission. DAS28 is significantly higher in
patients who flared which is associated with a parallel reduction in
expression of NKG2A. Figure 6B demonstrates a negative
correlation between DAS28 at six months follow-up and baseline
NKG2A expression (r =20.612; p=0.005).
Discussion
The development of TNFi has revolutionised the treatment of
inflammatory arthritis including RA leading to clinical, laboratory
and functional improvement [3–5]. Initially prescribing TNFi was
limited to patients who had failed a number of DMARDs,
however recent data has shown that early initiation of therapy may
reduce disability and future disease burden [3,24,25]. Recent
guidelines suggest treatment of RA to a target of remission (or low
disease activity in patients with established disease) with regular
review to allow escalation of therapy as necessary to reach these
targets. Therefore, potentially more patients will be prescribed
biologic therapies at an earlier stage in the disease process [26].
Limitations of early treatment include the costs involved in
treating patients with expensive medication for long time-periods,
increasing the financial burden on already over-stretched
healthcare systems. Furthermore, up to 30% of patients fail to
respond to TNFi, therefore prediction of response is an important
focus of research.
In this study, we identified markers in peripheral blood that
differentiate active RA patients from patients in remission. While
no difference was observed in the frequency of the CD3+CD562
populations between the three cohorts, expression of CD161,
CD57 and CD94/NKG2A by T cells was significantly increased
in the remission cohort versus active disease. Although
CD4
+CD28
2 cells are contained within this cell subset they were
not specifically assessed in the study. Following withdrawal of
TNFi, the expression of CD94 and NKG2A by T cells was
significantly increased in patients who remained in remission
versus patients whose disease flared. Finally, an inverse relation-
ship between the expression of NKG2A by T cells and DAS28 was
demonstrated. Therefore, specific populations of NKR+ lympho-
cytes in the circulation of RA patients is associated with response
Figure 2. Expression of CD161, HLA-DR and CD57 in active RA, Remission RA and healthy controls. (A) Representative dot plots of
CD161, HLA-DR and CD57 expression on healthy control, patient with active RA and patient in remission following TNF inhibitor therapy. (B) CD161,
HLA-DR and CD57 expression on CD3+CD562 cells in healthy controls (m), patients with active RA (#) and patients in remission following TNF
inhibitor therapy (&). *p,0.05 significantly different.
doi:10.1371/journal.pone.0027182.g002
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following withdrawal of TNFi, prior to clinical symptoms of
disease.
Approximately 30% of patients commencing on TNFi will enter
clinical remission (defined as DAS28,2.6). In our cohort of
patients, 45.45% flared within 6 months of stopping therapy
despite commencing optimal DMARDs at the time of cessation of
TNFi. Only one patient required recommencement of therapy
after flare with the other patients reaching the 6-month endpoint
off biologic therapy. Optimal DMARD therapy was commenced
at TNFi withdrawal as it has previously been demonstrated that
patients with established RA ceasing TNFi will flare following
cessation of therapy with median time to flare between 13.5 and
15 weeks [27].
Figure 3. Expression of NKRs CD94 and NKG2A in active RA, Remission RA and healthy controls. (A) Representative dot plots of CD94
and NKG2A expression on healthy control, patient with active RA and patient in remission following TNF inhibitor therapy. (B) CD94 and NKG2A
expression on CD3+CD562 cells in healthy controls (m), patients with active RA (#) and patients in remission following TNF inhibitor therapy (&).
*p,0.05 significantly different.
doi:10.1371/journal.pone.0027182.g003
Figure 4. Total CD3+, Total CD56+ and CD3+CD562 T cell populations in patients maintaining or withdrawing therapy. Graphs
illustrate total CD3+, Total CD56+ and CD3+CD562 T cell populations (expressed as a percentage of the lymphogate) in patients maintaining or
withdrawing therapy at baseline (m) and three months (#). *p,0.05 significantly different.
doi:10.1371/journal.pone.0027182.g004
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for remission induction with 70% of patients maintaining response
two years after withdrawal of infliximab therapy [28]. The BeST
study also demonstrated that early intervention with TNFi could
allow for withdrawal after a defined period, however a proportion
of patients in the infliximab/DMARD group required continua-
tion of biologic therapy [29,30]. Similar remission rates have been
demonstrated in the early commencement of other commercially
available TNFi. In clinical practice patients commencing on
therapy are maintained indefinitely on treatment once a clinical
response is achieved and the treatment is well tolerated. Patients in
clinical remission are also treated indefinitely and it is not clear if
increasing time between infusion or injection or institution of ‘drug
holidays’ will be tolerated. The duration of potential drug holidays
is also unclear. RA is a heterogeneous disease and it is logical that
some patients would tolerate longer drug holidays than others.
The effect of TNFi on NK receptor expression on T cells in RA
has not been systematically studied. A significant increase in T
cells expressing the NK receptors CD161, CD57, CD94/NKG2A
was observed in remission compared to active RA. The expansion
of CD161 was maintained in patients following withdrawal of
therapy however there was significant reduction in CD94/
NKG2A in patients who flared.
CD94 in association with NKG2A delivers inhibitory signals to
T cells recognising HLA-E. CD94/NKG2A expression which was
elevated in patients in remission compared to those patients with
active disease, suggests this molecule plays a key role in the
regulation of inflammation in RA. Supporting this hypothesis, it
has been shown that CD94/NKG2A plays a key role in the
regulation of pro-inflammatory events in RA [31]. IFNc and
TNFa production were markedly enhanced by antibody masking
of the CD94/NKG2A receptor in vitro, suggesting that CD94/
NKG2A is a key regulator of pro-inflammatory cytokine
production [31]. A significant reduction in circulating lympho-
cytes expressing CD94/NKG2A was demonstrated in patients
with new onset of psoriasis [32]. In addition, other studies have
examined the effect of targeting NKG2A+ NK cells in a mouse
model of autoimmune encephalomyelitis. Treatment of mice with
a CD94/NKG2A/C/E specific F(ab’)2 fragment enhanced NK
cell mediated elimination of activated autoreactive T cells resulting
in inhibition of inflammatory damage to spinal cord which was
associated with decreased infiltration of T cells [33]. Together
these suggest that CD94/NKG2A maybe an important molecule
involved in regulation of inflammation in a number of different
autoimmune diseases by different mechanisms.
We observed a significant increase in the expression of CD161 by
T cells in patients in remission. CD161 is a C-type lectin receptor,
butlittleisknownaboutitsfunctioninautoimmunediseases.CD161
and CD57 can both be expressed by NKT cells and are associated
with sub-population of CD4+ T cells [34,35]. Increased frequencies
of CD4+CD282 expressing CD161 and CD57 in patients with
active RA have been demonstrated [21,36–38], and CD4+CD161+
Figure 5. Expression of NKRs CD94, NKG2A, CD161 and CD57 in patients maintaining or withdrawing therapy. Graphs illustrate (A)
CD94 and NKG2A expression and (B) CD161 and CD57 expression at baseline (m) and three months (#) in patients maintaining or withdrawing TNF
inhibitor therapy. (C) Representative dot plots of two patients withdrawing TNF inhibitor therapy. Patient (I) remained in clinical remission for the
study duration and maintained expansion of CD94 and NKG2A; Patient (II) had a flare in disease activity 6 months after withdrawal of therapy with
loss of expansion of CD94 and NKG2A at 3 months (i.e. prior to clinical relapse). *p,0.05 significantly different.
doi:10.1371/journal.pone.0027182.g005
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aggregates [38], while CD57 expression may render cells more
susceptible to activation-induced cell death by apoptosis [39].
Recent studies have shown that sub-populations of CD4+ T-
cells that co-express CD161 and CCR6 are potent producers of
IL-17 suggesting CD161 is an important marker for human T-
helper cells producing IL-17 (Th17) [40]. While its precise role is
unclear, studies suggest that CD161 may regulate T cell adhesion,
transendothelial cell migration and invasion [41–43]. Consistent
with our results, studies have also shown a reduction in CD161+ T
cells in the inflamed mucosa of ulcerative colitis compared normal
control colon [44], and in psoriasis patients persistence of CD161
expression was demonstrated in plaques while lesional T-cell
subset were reduced following 16 weeks of therapy [45].
Furthermore, CD161 can partially inhibit TNFa production by
CD8+ T cells and therefore it may play a role in maintaining
remission in patients following withdrawal of TNFi [46]. CD57+
cells have also been implicated in the pathogenesis of RA through
secretion of pro-inflammatory cytokines [20,35], however some
studies have shown that CD57+ T cells from healthy subjects
suppress neutrophil development in vitro an effect that is impaired
in RA patients with Felty’s Disease and large granular lymphocyte
syndromes [47]. We also demonstrated a significantly higher
frequency of CD57
bright T cells in patients in remission compared
to active RA, however expression did not change when disease
flares following TNFi withdrawal. CD57
bright T cell express high
levels of cytolytic enzymes, have reduced proliferative rates, are
thought to be susceptible to activation-induced cell death and may
represent a functional ‘exhausted’ subset of T cells [48–50].
Although we observed a consistent increase of CD161 and CD57
expression by the T cells of the RA patients in remission, the exact
role CD161 and CD57 play in the pathogenesis and regulation of
inflammation in RA remains to be determined.
In conclusion, we present a small, but comprehensive dataset
demonstrating differences in CD94/NKG2A expression by T cells
in patients’ circulation measured at regular intervals following
therapy withdrawal and thus may precede disease flares in disease
activity, allowing the timely reinstitution of therapy. This may
allow for drug holidays in patients with RA in clinical remission
decreasing the economic burden of biologic therapies and allowing
reassurance to patients of a reduced likelihood of clinical flare in
disease activity.
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